KLOW 80mg – Lyophilized Research Material

Form: Lyophilized powder (80mg)

Components: Ghk-Cu(50mg), Bpc-157(10mg), TB-500(10mg), KPV(10mg)

🔬 KLOW (BPC-157 + TB-500 + KPV + GHK-Cu Combination) — Overview

KLOW is a multi-peptide research combination composed of BPC-157, TB-500, KPV, and GHK-Cu, designed for experimental investigation of tissue repair signaling, inflammation modulation, angiogenesis, and extracellular matrix remodeling. KLOW is not a single chemical entity, but a blend of four distinct peptides, each retaining its own molecular structure and biological role.

📌 Brief Functional Description

• Tissue repair & recovery signaling
  • BPC-157: Studied for localized tissue protection, angiogenic signaling, and nitric-oxide–related pathways.
  • TB-500: Studied for systemic cell migration, actin regulation, and angiogenesis.
• Inflammation modulation & barrier support
  • KPV: A tripeptide derived from α-MSH, studied for anti-inflammatory signaling, cytokine modulation, and gut/epithelial barrier integrity.
• Extracellular matrix & regenerative signaling
  • GHK-Cu: A naturally occurring copper-bound tripeptide studied for collagen synthesis, wound healing, antioxidant activity, and tissue remodeling.
• Complementary activity:
  The combination is used in research models to explore broad-spectrum regenerative and recovery signaling, spanning inflammation control, angiogenesis, connective tissue repair, and cellular remodeling.

🧪 Chemical & Structural Information

🔢 CAS Numbers

• BPC-157: 137525-51-0
• TB-500: 885340-08-9
• KPV: 67763-96-6
• GHK-Cu: 49557-75-7

(As a blend, KLOW does not have a unique CAS number.)

🧬 Molecular Formula

• BPC-157: C₆₂H₉₈N₁₆O₂₂
• TB-500: C₃₈H₆₈N₁₀O₁₄
• KPV: C₁₄H₂₂N₄O₅
• GHK-Cu: C₁₄H₂₄CuN₆O₄

⚖️ Molecular Weight

• BPC-157: ≈1,419.5 Da
• TB-500: ≈889.0 Da
• KPV: ≈330.3 Da
• GHK-Cu: ≈401.9–404.9 Da

🧬 Amino Acid Sequence & Structure

• BPC-157:
  • Linear 15-amino-acid peptide
  • Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
• TB-500:
  • Synthetic fragment derived from thymosin β-4
  • Active sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln
• KPV:
  • Tripeptide derived from α-MSH
  • Sequence: Lys-Pro-Val
• GHK-Cu:
  • Copper-chelated tripeptide
  • Sequence: Gly-His-Lys coordinated with Cu²⁺

General structural description:

Four independent peptides (two tripeptides, one 15-aa peptide, one thymosin fragment) acting through complementary pathways 

🧠 Mechanism & Biological Context

• BPC-157 contributes localized cytoprotection and angiogenic signaling.
• TB-500 supports actin dynamics, cell migration, and vascular remodeling.
• KPV modulates inflammatory signaling pathways, particularly in epithelial and immune-related research models.
• GHK-Cu influences extracellular matrix turnover, collagen synthesis, antioxidant defense, and regenerative gene expression.

Together, KLOW is explored in preclinical research to evaluate multi-pathway recovery, inflammation control, and tissue regeneration signaling beyond what single-peptide models provide.

⚠️ Safety & Regulatory Notes

• Research Use Only: None of the components are FDA-approved for therapeutic use.
• KLOW represents co-administration, not a chemically bonded compound.
• Components are often reconstituted separately in research settings due to stability and formulation considerations.

🧪 Quick Reference

Notice: For Research Use Only. Not for human or veterinary use.